Table 4.
Clinical trials of vaccines targeting IDHmt
| Trial | Drug | Phase | Target | Status | Histo. | Inclusion | Target |
|---|---|---|---|---|---|---|---|
| NOA-16 NCT02454634 | 20-mer, Montanide, Imiquimod | Phase I | IDH1R132H | LPO Q3/2017 | °III-IV | Newly diagnosed with RCTX | Safety, Immune |
| AMPLIFY-NEOVAC (NOA-21) NCT pending | 20-mer, Montanide, Imiquimod ± Avelumab | Phase I | IDH1R132H | FPI Q2 2018 | °II-IV | Recurrent after RCTX | Safety, Immune |
| IDH1R132H-DC NCT02771301 | Peptide on patient-autologous DCs | Phase I | IDH1R132H | Q1 2019 | °II-IV | ND with RCTX | Safety |
| RESIST NCT02193347 | 25-mer, Tetanus-Diphtheria-Toxoid | Phase 1 | IDH1R132H | Q2 2019 | °II | Progressive with TMZ | Safety, Immune |
Abbreviations: FPI, first patient in; LPO, last patient out; RCTX, radiochemotherapy; Q, quarter.